Angelica Salaverria represented the James Lab by recently presenting her work at the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research, held September 19–21, 2025, at the Grand Hyatt Denver in Denver, Colorado. Salaverria presented her poster, entitled “Amphiregulin neutralization reduces tumor burden and combats immunosuppression within the ovarian tumor microenvironment.”

The AACR’s biennial conference serves as a premier forum for scientists, clinicians, and industry leaders to discuss the most recent advances in ovarian cancer biology and treatment. This year’s meeting explored topics ranging from tumor initiation and heterogeneity to novel immunotherapies, biomarker-driven precision medicine, and antibody-drug conjugates (ADCs). It also emphasized emerging technologies such as artificial intelligence, multi-omics, and single-cell analysis, which are rapidly reshaping the landscape of cancer diagnosis and therapeutic development.

Ovarian cancer remains one of the most challenging malignancies to treat—despite progress, it is still the most lethal gynecologic cancer and the fifth leading cause of cancer-related death among women in the United States. With an estimated 19,680 new cases and 12,740 deaths in 2024, continued research efforts like Salaverria’s are vital to improving patient outcomes.

Her participation in this high-profile conference not only showcased her scientific rigor but also contributed to the broader dialogue on overcoming therapeutic resistance and improving survival for patients with ovarian cancer.